CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bharat H. Barai who wrote (288)	8/31/1999 1:20:00 AM
From: Vector1	Read Replies (2) of 666

Dr. Barai, Thanks for the most informative post. Interesting comment on Gemcitabine. How Lilly ever got that through the FDA I will never know. I guess they will approve almost anything for Pancreatic Cancer. You are quite right on off label usage. It is a classic strategy of major pharma in the oncology area to get a drug approved for a niche indication and then conduct additonal trials and have articles published to sell off label. A company's right to use published articles has been enforced by the courts. Any thoughts on how well Bexxar will work in combination with Fludarabine. Pre-clinical studies showed synergy and CLTR is presenting on the trial in December at ASH. The trial is being conducted at Cornell Medical Center in NY. IMO once Bexxar is approved the treatment options for first line patients will be (i)Rituxan plus CHOP (ii)Bexxar(iii)Bexxar plus Fludarabine. V1

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next